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Background: Among the many definitions of frailty, the frailty phenotype defined by Fried et al. is one of few
constructs that has been repeatedly validated: first in the Cardiovascular Health Study (CHS) and subsequently in
other large cohorts in the North America. In Europe, the Survey of Health, Aging and Retirement in Europe (SHARE) is
a gold mine of individual, economic and health information that can provide insight into better understanding of
frailty across diverse population settings. A recent adaptation of the original five CHS-frailty criteria was proposed to
make use of SHARE data and measure frailty in the European population. To test the validity of the SHARE
operationalized frailty phenotype, this study aims to evaluate its prospective association with adverse health
outcomes.
Methods: Data are from 11,015 community-dwelling men and women aged 60+ participating in wave 1 and 2 of
the Survey of Health, Aging and Retirement in Europe, a population-based survey. Multivariate logistic regression
analyses were used to assess the 2-year follow up effect of SHARE-operationalized frailty phenotype on the
incidence of disability (disability-free at baseline) and on worsening disability and morbidity, adjusting for age, sex,
income and baseline morbidity and disability.
Results: At 2-year follow up, frail individuals were at increased risk for: developing mobility (OR 3.07, 95% CI, 1.02-
9.36), IADL (OR 5.52, 95% CI, 3.76-8.10) and BADL (OR 5.13, 95% CI, 3.53-7.44) disability; worsening mobility (OR 2.94,
95% CI, 2.19- 3.93) IADL (OR 4.43, 95% CI, 3.19-6.15) and BADL disability (OR 4.53, 95% CI, 3.14-6.54); and worsening
morbidity (OR 1.77, 95% CI, 1.35-2.32). These associations were significant even among the prefrail, but with a lower
magnitude of effect.
Conclusions: The SHARE-operationalized frailty phenotype is significantly associated with all tested health
outcomes independent of baseline morbidity and disability in community-dwelling men and women aged 60 and
older living in Europe. The robustness of results validate the use of this phenotype in the SHARE survey for future
research on frailty in Europe.
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Associated with old age, but a unique entity, frailty is
conceptualized as a state in which reserve function
across multiple physiologic domains decline, comprom-
ising the individuals’ capacity to withstand stress, thereby
predisposing them to poor health, functional decline,
institutionalization and death [1-6]. Due to the complex
multi-system and heterogeneous nature of the concept,
frailty definitions abound [7]. There is no clear consen-
sus on how to operationalize it [8-10] and the lack of a
gold standard impedes comparisons across time, coun-
tries, and populations in a reliable manner.
Among the many biological, physiological, social and
psychosocial models on the possible causes and path-
ways of frailty [1,11-18], the one that has attracted con-
siderable attention is the “phenotype of frailty” [1]. This
concept embodies a set of signs and symptoms that is
well aligned with geriatric syndromes, underscoring a
biological origin, and reflecting a syndromic character in
which an aggregate of multiple-system impairments that
are inter-related cause a loss of function [19-21]. As one
of most widely-referenced constructs, the frailty pheno-
type is defined by the presence of three or more of the
five specific measurable attributes: weight loss, muscle
weakness, poor endurance, slow motor performance and
reduced physical activity [1].
Using data from the Cardiovascular Health Study (CHS),
Fried et al. operationalized the phenotype and confirmed its
validity by showing association with 3 and 7-year incidence
of mobility and ADL disability, independent of comorbidity
among community-dwelling men and women aged 65 years
and older [1]. Subsequently, numerous validation studies,
including two large cohort studies carried out by Woods
et al. [22] and Bandeen-Roche et al. [23], used the same
construct with some modifications in the metric used to
define each frailty criteria. In spite of these differences, the
frailty criteria persisted in showing strong independent
associations to poor health outcomes. By testing the criteria
and their modifications in different populations these stud-
ies substantiate, to a greater extent, the generalizability of
the frailty phenotype in the North America populations.
In Europe, the large multi-country and ongoing
population-based panel survey of health, social, and eco-
nomic well-being of community dwellers aged 50 and
older, entitled Survey of Health, Aging and Retirement
in Europe (SHARE) offers an important opportunity to
investigate the disparities of health and their determi-
nants. With as many as 20 countries of the European
Union participating, SHARE’s rich and detailed multidis-
ciplinary data source is a promising medium to explore
the relationship between frailty and its diverse environ-
ment in Europe.
With this in view, using data from SHARE, Santos-
Eggimann and colleagues [24] operationalized the Friedfrailty criteria by selecting the most suitable metric available
and applied it to the first wave of SHARE in order to
quantify the burden of frailty across populations in Europe.
Since there was considerable divergence from the metric
used in the CHS study to define the frailty phenotype, it
was necessary to test the SHARE-adapted metric’s pro-
spective association with adverse outcomes in the SHARE
population. Advancing on the work of Santos-Eggimann
and colleagues, Romero-Ortuno and colleagues used the
SHARE - operationalized phenotype and successfully
demonstrated its validity in predicting mortality [25].
Testing and validating the operationalization of sound
conceptual models is a necessary first step in assessing
its reproducibility and reliability in diverse populations
for cross country comparisons to be made possible over-
time. Hence, to further the confidence in the validity of
the SHARE metric, this paper assesses, among the survi-
vors, the prospective association of the frailty criteria, as
operationalized in SHARE, on incident mobility, BADL
and IADL disability, and on worsening mobility, disabil-
ity and morbidity over a 2-year follow-up in community
dwelling women and men aged 60 and older taking part
in the SHARE survey.
Methods
Data source and sample
Data are derived from (SHARE, release 2.4.0) 11 countries
of the European Union (Austria, Belgium, Denmark,
France, Germany, Greece, Italy, The Netherlands, Spain,
Sweden, and Switzerland) that participated in the 2004 and
2006 wave of SHARE. Representative samples of non-
institutionalized population aged 50 years and older [26]
were drawn from national or regional population based
registries using simple or multistage probably sampling
techniques, depending upon the institutional framework of
each country. Data for wave1 were collected in 2004 and
followed up in 2006 for wave2 using computer-assisted per-
sonal interview technique (CAPI) by trained interviewers.
Mean response rates were 62%. Detailed description of the
SHARE Methodology is documented on the SHARE
website [27].
The study eligibility criteria was set up to include all indi-
viduals who had participated in both the baseline interview
and consented to follow up; born prior to 1945; and
reported to be living at home at the time of the interview in
2004. Of the 18, 105 non-institutionalized individuals aged
60+ who participated in 2004, 539 were reported deceased,
5,966 were lost to follow up, and 585 refused further par-
ticipation in 2006, resulting in a study sample of 11,015
individuals.
Frailty definition
Frailty was operationalized using variables in SHARE
[24] that approximated those used in the original CHS
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ness was measured using a dynamometer, using the
highest of 4-measurement readings (2 from each hand)
of handgrip strength after adjusting for gender and body
mass index cutoffs as specified by L. Fried [1]. Exhaus-
tion criterion was met if the participant answered “yes”
to the self-reported question: “In the last month have
you had too little energy to do things you wanted to
do?”. Unintentional weight loss was operationalized using
2 questions in SHARE: 1) “What has your appetite been
like?” and/or 2) “So have you been eating more or less?”.
Participants scored positive for the criterion if they
answered either “Diminution in desire for food” in re-
sponse to the first question, or “Less” in response to the
second question. Slowness was operationalized using two
questions: “Because of health problems, do you have dif-
ficulty walking 100 m, or climbing one flight of stairs
without resting?”. Criterion was met if participants
answered positive to either of the two questions. Low
physical activity was operationalized using the question
“How often do you engage in activities that require a
low or moderate level of energy such as gardening,
cleaning the car or going for a walk?”. Participants
scored positive for the criterion if responded “One to
three times a month, hardly ever, or never”. Subjects
were considered frail if they met three or more of these
criteria; prefrail if they fulfilled one or two criteria; and
not frail if they met none.
Outcome measures
Seven outcomes were examined to assess the robustness
of the SHARE-operationalized frailty criteria in predict-
ing adverse health in the SHARE sample. A 2-year inci-
dence and a 2-year propensity for “worsening” were
computed for each of 3 dimensions of functional disabil-
ity (mobility, IADL and BADL) as well as a 2-year wor-
sening of morbidity.
Functional disability
Mobility disability was defined by self-report of difficulty
in any one of the 8 upper and lower extremity mobility
function tasks on the Rosow - Breslau scale [28]: sitting
for 2 hrs; getting up from a chair; climbing several flights
of stairs without resting; climbing 1 flight of stairs with-
out resting; stooping or kneeling; reaching or extending
arms above shoulder; pulling/pushing large objects, and
lifting objects of 5 kg. IADL disability was defined by
self-report of difficulty in any one of the 7 IADL tasks
on the Lawton-Brody scale [29]: using a map; preparing
a hot meal; shopping for groceries; using a telephone;
taking medications; doing work around the house; and
managing money and paying bills. BADL disability was
defined by self-report of difficulty in any one of the 5
BADL tasks on the Katz ADL scale [30]: dressing;bathing; getting in and out of bed; toileting; and eating
and/or cutting up food. In each of these three dimen-
sions, participants were asked: “Please tell me whether
you have any difficulty doing each of the everyday activ-
ities on the card?”. Difficulties that were anticipated to
last less than 3 months were excluded.
Incident mobility, IADL and BADL disability at 2-year
follow was defined as the development of any “new”
reported difficulty observed over the 2 year period, in ei-
ther of the 3 respective functional disabilities, and com-
puted among only those subjects free of the specific type
of disability at baseline. Worsening of mobility, IADL and
BADL disability at 2-year follow was defined as any in-
crease, with respect to baseline, in one or more number
of reported difficulties in mobility, IADL, and/or BADL
among subjects not already disabled at baseline in all the
tasks of the respective functioning domains. It was cal-
culated by taking the difference between the numbers of
difficulties reported at follow-up (2006) and those
reported at baseline. It was coded “0” if no change or
improvement, and “1” if an increase was observed in the
number of difficulties within each specific domain of
functional disability.Morbidity
Morbidity was defined according to the chronic disease
list formulated by Fried and colleagues in the Cardiovas-
cular Health Study [1]. The following 7 self-reported
chronic diseases were selected and evaluated: 1) myocar-
dial infarction, congestive heart failure, angina, periph-
eral vascular disease; 2) stroke; 3) HBP or hypertension;
4) diabetes mellitus; 5) chronic obstructive pulmonary
disease; 6) rheumatoid arthritis, and 7) cancer. As parti-
cipants could answer to more than one concurrent con-
dition, a total count was calculated by summing up the
frequency reported by each individual at baseline. Wor-
sening morbidity at 2-year follow up was defined as an
increase with respect to baseline, in one or more num-
ber of chronic conditions observed among individuals
who did not already accumulate all 7 diagnoses. It was
coded “0” if no change or improvements were observed,
and “1” if an increase (difference between follow up and
baseline count of > = 1) in the number of chronic condi-
tions were observed.
Control variables
Sex, age (in years), and income (defined by the purchas-
ing power of parity (PPP) household income adjusted for
family size transformed to a logarithmic scale) were con-
sidered as potential confounders. Although education
was considered, it was not retained due to its high cor-
relation with income. Baseline morbidity was also con-
sidered as a control variable, and thus was categorized
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and 2+ chronic conditions (multi-morbidity).
Statistical analysis
Using STATA statistical software program version 11, all
statistical analyses were weighted to account for the in-
dividual country’s complex sampling schemes. Four pri-
mary sampling units were removed due to the inability
to compute variance. Weighted proportions were used
to describe baseline characteristics of the sample popula-
tion and chi-square tests were performed to assess dif-
ferences between the sexes. Further, bivariate analyses
were carried out to assess the relationship between
frailty and the 7 outcomes using chi-square tests of inde-
pendence. Finally, multivariate logistic regression ana-
lyses were used to assess the effect of the SHARE-
operationalized frailty phenotype on the incidence and
worsening of functional capacity as well as on worsening
of morbidity at 2-year follow up.
Two multivariate models were computed for each of
the 3 incidence outcomes (incident mobility, IADL and
BADL disability) to test their independent association
with frailty over a 2-year follow up. The first model
adjusted for demographic variables of age and sex; the
second model further adjusted for income and baseline
morbidity. Two multivariate models were also computed
for each of the 3 “worsening” outcomes (worsening mo-
bility, IADL and BADL disability). The first model
adjusted for age, sex and disability-specific domain at
baseline; the second model further adjusted for income
and baseline morbidity. Finally, 2 additional multivariate
models were computed to assess the effect of frailty onTable 1 Wave 1 population baseline characteristics (weighted
Variable Wave 1 ALL
Outcome %
(weighted prop)
Frailty Not frail 46.0
Pre-frail 41.1
Frail 12.9
Age 60-64 26.4
65-69 23.9
70-74 19.5
75-79 15.0
80-84 10.8
85+ 4.1
Functional status Mobility (1+) 59.0
BADL (1+) 12.9
IADL (1+) 19.6
Morbidity Morbidity (1) 37.0
Comorbidity (2+) 30.6worsening morbidity. The first model adjusted for age,
sex and baseline morbidity; the second fully adjusted
model also included income status.
Results
Table 1 shows the baseline burden of frailty, functional
disability and morbidity by sex in 11,015 community
dwelling men and women aged 60 years and older living
in selected European countries. Mean age was 70 years
for men and 71 years for women. The SHARE-
operationalized frailty phenotype was assessed in 10,237
participants and classified 46.0% as non-frail, 41.1% as
pre-frail, and 12.9% as frail. The sex–specific prevalence
showed women to be almost twice as likely to be frail
(16.4% vs. 8.6%), but only moderately more likely to be
pre-frail (43.4% vs. 38.1%) than men. Women also self-
reported to be more functionally dependent and morbid
than men – as measured by mobility (67.8% vs. 47.5%),
IADL (24.8% vs. 12.9%), BADL (15.0% vs. 10.2%) and
multi-morbidity (32.6% vs. 28.1%).
Table 2a shows the overall 2-year incidence of mobility
(34.5%), IADL (14.8%) and BADL (8.8%) disability
among the SHARE sample. The unadjusted risk of func-
tional disability was greatest among frail, and to a lesser
extent pre-frail compared to non-frail individuals. Frail
individuals had more than 7-fold risk of developing
BADLs disability; more than a 5-fold risk of developing
IADL disability, and only a 2.5 fold risk of developing
mobility disability compared to non-frail individuals.
Table 2b shows that among individuals who were not
already disabled in all tasks at baseline, the 2-year un-
adjusted propensity for worsening was consistentlyproportions)
Male Female Chi2
% % P Value
(weighted prop) (weighted prop)
53.2 40.2 0.000
38.1 43.4
8.6 16.4
28.8 24.5 0.000
26.2 22.2
19.9 19.2
13.8 15.8
8.2 12.8
3.1 5.6
47.5 67.8 0.000
10.2 15.0 0.000
12.9 24.8 0.000
37.0 37.0 0.000
28.1 32.6
Table 2 Bivariate relationship between frailty in 2004 and
outcomes in 2006
Wave 2 (2006) Overall Non-frail Pre-frail Frail Chi2
a) INCIDENCE1 % % % % p
Mobility 34.5 29.3 43.1 70.5 0.000
IADL 14.8 7.9 18.5 45.3 0.000
BADL 8.8 4.4 9.6 31.6 0.000
b) WORSENING2
Mobility 35.6 28.9 39.0 49.7 0.000
IADL 16.4 7.9 19.0 38.9 0.000
BADL 10.5 19.0 10.9 30.9 0.000
Morbidity 26.3 4.3 26.8 31.8 0.003
1Limited to individuals with no prevalent disability at baseline.
2Limited to individuals not at the maximum level of disability or morbidity
at baseline.
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(49.7% and 39.0%), IADL (38.9% and 19.0%) and BADL
(30.9% and 10.9%) disability, respectively. In contrast,
the likelihood of worsening morbidity among individuals
who did not report all 7 diagnoses at baseline only
slightly declined across the frailty gradient: 31.8% forTable 3 Multivariate relationship between frailty in 2004 and
a) INCIDENCE1 Control variables n
Mobilty a 4813
b 4795
IADL a 8531
b 8495
BADL a 9217
b 9176
b) WORSENING2
Mobility c 10138
d 10094
IADL e 10177
f 10133
BADL g 10187
h 10143
Chronic Conditions i 10197
j 10156
*p values <0.05 significant.
aAge and sex.
bAge, sex, income and morbility at baseline.
cAge, sex, baseline mobility.
dAge, sex, baseline mobility, income and baseline morbidity.
eAge, sex, baseline IADL.
fAge, sex, baseline IADL, income and baseline morbidity.
gAge, sex, baseline IADL.
hAge, sex, baseline IADL, income and baseline morbidity.
iAge, sex, baseline morbidity.
jAge, sex, baseline morbidity and income.
1Limited to individuals with no prevalent disability at baseline.
2Limited to individuals not at the maximum level of disability or morbidity at baselifrail, 26.8% for pre-frail, and 24.3% for non-frail
individuals.
Table 3a shows frailty to be independently associated
with an increased incident mobility (OR 3.07), IADL
(OR 5.52) and BADL (OR 5.13) disability. The pre-frail
category was also statistically significant, but with a
smaller magnitude of effect. Table 3b shows that over a
2-year follow-up period, frailty was independently
associated with increased odds of worsening disability
(mobility, IADL and BADL) and of worsening morbidity,
after fully adjusting for potential confounders. Frail indi-
viduals were around twice as likely as pre-frail indivi-
duals to worsen on all three functional disabilities. In
contrast, the strength of association between frailty and
worsening morbidity was weaker for both frail (OR 1.77)
and pre-frail (OR 1.30) individuals, but nonetheless
significant.
Discussion
Using pooled data from across 11 European countries,
the SHARE-operationalized frailty phenotype showed
strong and significant prospective association with func-
tional decline and morbidity in community-dwellingoutcomes in 2006
Pre frail Frail
OR CI OR CI
1.59 1.31-1.92 4.10 1.42-11.84
1.47 1.21-1.80 3.07 1.02-9.26
2.14 1.73-2.64 6.47 4.49-9.34
1.98 1.60-2.46 5.52 3.76-8.10
1.85 1.41-2.42 6.47 4.56-9.19
1.65 1.25-2.17 5.13 3.53-7.44
1.63 1.41-1.87 3.18 2.40-4.22
1.55 1.35-1.78 2.94 2.19-3.93
2.27 1.86-2.77 5.11 3.75-6.99
2.11 1.72-2.60 4.43 3.19-6.15
2.14 1.66-2.77 5.59 3.94-7.96
1.91 1.47-2.49 4.53 3.14-6.54
1.33 1.14-1.55 1.88 1.45-2.45
1.3 1.12-1.52 1.77 1.35-2.32
ne.
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The findings indicate that even after adjusting for age,
sex, income and baseline disability or morbidity, frailty
persisted to be independently associated with developing
mobility, IADL and BADL disability over a 2-year follow
up. The SHARE-operationalized frailty phenotype was
also significantly associated with worsening mobility,
IADL respectively BADL disability, and chronic diseases
independent of age, sex, income, and baseline disability
and morbidity over a 2-year follow up. Moreover, the
risk of functional decline and morbidity was present
even among the pre-frail, but with a slightly lower mag-
nitude of effect. This is consistent with the empirical evi-
dence that the risk of disability and/or morbidity for
those presenting with 3 or more frailty components is
much higher than when 1 or 2 components are pre-
sented, and still greater than when no criteria is present.
These results suggest that the metric used in SHARE to
operationalize the frailty phenotype construct, as
described in the original CHS by Fried and colleagues, is
robust in identifying a subgroup of vulnerable older
populations at risk for developing adverse outcomes.
The results presented here are in line with previous
studies validating the frailty phenotype for a range of ad-
verse outcomes [22,23,31-36]. Data from the Cardiovas-
cular Health Study (CHS) showed frailty and prefrailty
to be independently associated with worsening mobility
and ADL disability [1]. Similarly data on women aged
65–79 from the WHIOS indicated baseline frailty to in-
dependently predict ADL disability for frail and pre-frail
individuals after adjustments for socio-demographic, dis-
ability and co-morbid conditions [22]. Data from
WHASI & II found frailty to be significantly associated
with a 3-year incidence of IADL and ADL disability
among frail and pre-frail individuals after adjustments
[23]. The findings of this study also concur with Euro-
pean studies that have explored frailty in its broader
sense in relation to disability, morbidity, and mortality
[25,37-40]. The 3 French City Study, for example, found
frailty to be significantly associated with a 4-year
incidence of disability in ADL and IADL after
adjustments [37].
While the strength of associations concur, the magni-
tude of the associations differ from study to study – in-
evitably due to study design, sample size, study
populations’ health characteristics at baseline and spe-
cific conditions that define the sample population para-
meters such as inclusion and exclusion criteria, and
particular to this study, the specific metrics used to
operationalize the frailty definition. For example, in
comparison to studies mentioned above, the SHARE
population reported higher baseline burden of frailty,
disability and morbidity; its eligibility criteria did not ex-
clude cognitively impaired or terminally ill subjects; itssample was composed of both men and women, and the
follow up time was 2 years. However, it also shared some
similarities with the studies above, such as: a large sam-
ple size of community dwelling older adults aged 60 and
older; a prospective follow up and use of the widely
accepted frailty phenotype construct proposed by Fried
and colleagues.
In spite of similarities and differences in study scope,
design, and population characteristics, the heterogeneity
in the prevalence of frailty remains largely a function of
the operationalization and assessment of each criteria
that defines the phenotype, which is mostly likely to dif-
fer from survey-to-survey due to the difference in its
conceptualization, language formulation and measure-
ment [18,37,40-46]. For example, the SHARE operatio-
nalization of “weakness” as measured by grip strength
differed from that in the InChianti study conducted in
Italy [40] and the Toledo Study on Health and Aging
study conducted in Spain [47] in that both of these stud-
ies used their own lowest quintile cut-offs for their
underlying population, adjusted for sex and BMI, com-
pared to the sex and BMI specific cut points used in the
original CHS population set by Fried [1]. In another in-
stance, the absence of available data on grip strength
prompted the use of a self-reported question on the dif-
ficulty in rising from a chair as proxy measure for the
weakness criterion [37,38]. These discrepancies may ex-
plain some of the observed differences in frailty preva-
lence found in surveys conducted in Italy (8.8%) [40],
Spain (8.4%) [47], and France (7%) [37]. Furthermore, in
a German cohort, Saum and colleagues demonstrated a
lower overall prevalence of frailty when using population
or country specific lowest quintiles (6.5%) compared to
population-independent cutoffs (8.9%) [48]. To reduce
the heterogeneity in reporting frailty, standardization of
cut points for the phenotype criteria may be the best vi-
able option for making comparisons across culturally,
economically, and socially diverse populations such as
those found in SHARE countries more meaningful, espe-
cially since the association with adverse health outcomes
has been validated in many countries.
This study found an association between frailty and
worsening of morbidity, as measured by the deterior-
ation in the number of select chronic conditions with re-
spect to baseline. While a few researchers have used
“worsening” as a metric to better understand the dy-
namic relationship between frailty and disability, it has
been largely in relation to functional status [39]. SHARE
data showed that while the odds ratio for worsening of
morbidity was smaller than that for functional disability,
it was not negligible. Moreover it showed significant
values for prefrail individuals with slightly reduced
strength of association. Although the odds ratios for the
incidence and worsening models are of similar magnitude,
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sening models are more narrow than that for incidence
models, revealing more precise estimates – which may
be due to the use of a larger analytical sample than
one limited to a subset of those free of disability at
baseline. Under resource and sample size constraints, a
more dynamic metric such as “worsening” functional
disability and worsening morbidity might serve to be
more efficient.
This data further delineates the significant difference
between frailty and prefrailty. In addition to the non-
negligible difference in magnitude between frailty en-
tities across all adverse outcomes, the observed data
suggests presence of a nonlinear relationship - arguing
for examining frailty on a continuous scale to better
explore its dynamic and interdependent properties.
The major strength of this study is first, the reference
to the widely adopted frailty phenotype, a construct that
has a sound theoretical basis showing good content,
construct, concurrent and predictive validity across di-
verse populations in both clinical and community set-
tings [34,41]. Second, while the variables selected in
SHARE depart from the original frailty criteria operatio-
nalized in the CHS study, this study attempted to mirror
as many ‘original’ definitions in order to ensure valid
comparisons as well as minimize any potential differen-
tial misclassification of outcome status. Three examples
are highlighted: the use of the same chronic condition
list, the incorporation of all 15 functional status items to
assess disability, and the use of the same BMI and gen-
der specific cut points to measure grip strength, all of
which were established as per Fried et al. in the original
CHS study. Third, the participation of 2 waves has lent
itself in creating a longitudinal dimension allowing for a
prospective analysis to be possible. Highly significant
odds ratios have been found in spite of a relatively short
2-year follow up interval. Fourth, the risk of incident
and worsening of functional status and morbidity is
present even among the prefrail, after adjustments.
Results suggest a possible gradient effect of frailty on ad-
verse outcomes where changes in as little as 1 or 2 frailty
criteria can impact on destabilizing a carefully balanced
homeostatic physiological state into a vulnerable one.
Fifth, the study’s large and diverse population-based
sample covering 11 European countries of wide eco-
nomic, social and cultural heterogeneity ensures greater
generalizability to the community-dwelling Europeans
aged 60+ as well as greater certainty around the point
estimates. Lastly, this study includes a new metric: “wor-
sening” of morbidity. “Worsening of morbidity”, as an al-
ternative to “incidence of morbidity”, is a useful
outcome to consider for both prevention and treatment
strategies in aging population where chronic diseases
dominate the health burden.However a number of limitations must be made note.
First, this study reports a substantial proportion of attri-
tion. This is not an uncommon finding in large popula-
tion-based, multi-country, prospective studies. The
analyses of baseline characteristics of the untapped data
(lost to follow-up, refusals, deaths) reveal that this group
tended to be younger (65 vs. 70), while sex status was
non-differential. This group was only slightly more pref-
rail or frail (49%) compared to those in the analytical
sample (45%). Attrition may potentially lead to a selec-
tion bias that might have spuriously resulted in a
“healthy aging” effect. However, due to small differences,
it is unlikely to compromise the interpretation of the
results. Second, while the definition of morbidity used in
this study was directly adopted from the CHS to show
alignment and comparability with Fried et al., the meas-
ure is somewhat limited in the number and type of
chronic diseases that it contains. For example, it omits
prevalent conditions encountered in older persons such
as dementia, degenerative arthritis, and mental health
conditions. In contrast, this study used broad and rather
non-specific criteria defining mobility disability consist-
ent with other studies examining the relationship be-
tween frailty and disability [1,37,38]. The incidence of
mobility disability among the frail, prefrail and non-frail
groups in SHARE demonstrated to be of similar magni-
tude across the frailty gradient of that found in 3 City
French study: frail (70.5% vs 68%), prefrail (43% vs 55%)
and non frail (29% vs 45%) [37]. And finally, inherent to
all survey data is the reliance on “self-reported” informa-
tion which is limited by its inability for independent
verification. Self-reported data pose differential mis-
classification bias by sex, country or health status, and
must be taken into account when interpreting results. In
general, caution must be taken when making compari-
sons across countries, in that the variability in time,
place and people will always exist.Conclusions
The SHARE-operationalized frailty phenotype has estab-
lished good construct validity by showing significant associ-
ation with adverse outcomes, independent of baseline
disability and comorbidity in the European population aged
60 and older. These findings provide fertile ground for in-
vestigating more complex interactions of biological, envir-
onmental and social circumstances that impact on heath
trajectories, and shape the heterogeneity of frailty in aging
populations. SHARE, with its wide-scope and detail pro-
spective data on individual, economic, social, and environ-
mental and health characteristics, is the ideal medium to
further epidemiological research on frailty and health
in Europe.
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